Currently Viewing:
The American Journal of Managed Care February 2013
Are Benefits From Diabetes Self-Management Education Sustained?
JoAnn Sperl-Hillen, MD; Sarah Beaton, PhD; Omar Fernandes, MPH; Ann Von Worley, RN, BSHS, CCRP; Gabriela Vazquez-Benitez, PhD, MSc; Ann Hanson, BS; Jodi Lavin-Tompkins, RN, CNP, CDE, BC-ADM; William Parsons, MS; Kenneth Adams, PhD; and C. Victor Spain, DVM, PhD
Impact of Oral Nutritional Supplementation on Hospital Outcomes
Tomas J. Philipson, PhD; Julia Thornton Snider, PhD; Darius N. Lakdawalla, PhD; Benoit Stryckman, MA; and Dana P. Goldman, PhD
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Michael E. Chernew, PhD; Rick McKellar, BS; Wade Aubry, MD; Roy Beck, MD, PhD; Joshua Benner, PharmD, ScD; Jan E. Berger, MD, MJ; A. Mark Fendrick, MD; Felicia Forma, BSc; Dana Goldman, PhD; Anne Peters, MD; Rebecca Killion, MA; Darius Lakdawalla, PhD; Douglas K. Owens, MD; and Joe Stahl, MA
Oral Nutritional Supplementation
Gordon L. Jensen, MD, PhD
Medical Homes Require More Than an EMR and Aligned Incentives
Samantha L. Solimeo, PhD, MPH; Michael Hein, MD, MS; Monica Paez, BA; Sarah Ono, PhD; Michelle Lampman, MA; and Greg L. Stewart, PhD
Do Electronic Medical Records Improve Diabetes Quality in Physician Practices?
Jeffrey S. McCullough, PhD; Jon Christianson, PhD; and Borwornsom Leerapan, MD, PhD
Currently Reading
Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy
Suja S. Rajan, MHA, MS, PhD; William R. Carpenter, MHA, PhD; Sally C. Stearns, PhD; and Gary H. Lyman, MD, MPH
Spending and Mortality in US Acute Care Hospitals
John A. Romley, PhD; Anupam B. Jena, MD, PhD; June F. O'Leary, PhD; and Dana P. Goldman, PhD
Cost-Effectiveness of Medicare Drug Plans in Schizophrenia and Bipolar Disorder
Kenneth J. Smith, MD, MS; Seo Hyon Baik, PhD; Charles F. Reynolds III, MD; Bruce L. Rollman, MD, MPH; and Yuting Zhang, PhD
Introducing Forensic Health Services Research
Laurence F. McMahon Jr, MD, MPH; and Vineet Chopra, MD, MSc
Guidance for Structuring Team-Based Incentives in Healthcare
Daniel M. Blumenthal, MD, MBA; Zirui Song, PhD; Anupam B. Jena, MD, PhD; and Timothy G. Ferris, MD, MPH

Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy

Suja S. Rajan, MHA, MS, PhD; William R. Carpenter, MHA, PhD; Sally C. Stearns, PhD; and Gary H. Lyman, MD, MPH
Granulocyte colony-stimulating factor therapy reduces hospitalizations and improves chemotherapy administration in elderly breast cancer patients, but increases overall Medicare costs during first year of therapy.
Background: Chemotherapy is vital for breast cancer treatment, but early-onset toxicities like neutropenia hinder its administration. Neutropenia also increases costs due to hospitalizations and aggressive systemic antibiotic administration. Primary prophylactic (PP) use of granulocyte colony-stimulating factor (G-CSF) helps prevent neutropenia. However, evidence supporting the cost-effectiveness of PPG-CSF is inconclusive, and American Society of Clinical Oncology guidelines state the need for performing cost analyses in high-risk groups like the elderly.


Objectives: To examine the effect of PPG-CSF administration on neutropenia hospitalization costs and overall Medicare costs during the year following chemotherapy initiation.


Methods: A retrospective observational study of patients newly diagnosed with breast cancer between 1994 and 2002 was performed using the linked SEER-Medicare database. To account for the nonrandom nature of observational data, a covariate matching technique was used to preprocess the data before performing parametric analysis estimating the effect of PPG-CSF on costs.


Results: Administration of PPG-CSF during the first course of chemotherapy was associated with a 57% increase in overall Medicare costs during the study period, despite a drop in neutropenia hospitalization costs. Forty-two percent of the increase in costs was due to increase in chemotherapy costs during the year after chemotherapy initiation.


Conclusions: A significant part of the increase in immediate medical costs in breast cancer patients receiving PPG-CSF is due to improved chemotherapy administration. It is important to determine whether these short-term cost increases lead to long-term health benefits and savings. Cost analyses with longer follow-ups are crucial for chronic diseases like breast cancer.


(Am J Manag Care. 2013;19(2):150-159)
Our past studies show granulocyte colony-stimulating factors (G-CSFs) are effective in preventing neutropenia and neutropenia-related hospitalizations, and improving chemotherapy administration in elderly breast cancer patients.

  •  The current study shows that G-CSF use increases overall Medicare costs during the first year of breast cancer therapy by 57%.

  • This increase is chiefly due to improved chemotherapy administration in the first year. Hence, G-CSFs might improve long-term health benefits and reduce long-term costs for Medicare beneficiaries suffering from breast cancer.
Chemotherapy is vital for breast cancer treatment because it prevents recurrence and reduces mortality.1-8 Despite the demonstrated efficacy of first-course chemotherapy, compliance with recommended therapy is limited by chemotherapy-induced acute toxicities like neutropenia. Neutropenia is one of the most common reasons for chemotherapy dose reductions, delays, or discontinuation.9-11 Chemotherapy dose reductions make it difficult to prevent tumor regrowth, reduce chemotherapy effectiveness, increase the probability of recurrence and mortality, and might also increase the overall treatment costs.9,10,12-19 The rate of neutropenia is especially high among the elderly (age >65 years).20

The primary prophylactic (PP) use of granulocyte-colony stimulating factor (G-CSF) helps prevent neutropenia and sustain chemotherapy dose intensity.9,16,21-24 Use of PPG-CSF can also reduce costs associated with neutropenia-related hospitalizations and systemic antibiotic administration used to treat neutropenia-associated infections and fever.

More than 60,000 neutropenia hospitalizations occur each year in the United States,25 and each hospitalization could cost $10,000 to $30,000 on average.26-29 Administration of PPG-CSF might offset neutropenia hospitalization costs by reducing both the probability21,24,30-32 and duration21,26,33 of hospitalization. Other factors that might reduce costs for patients receiving PPG-CSF during the first year after diagnosis (when bulk of the cancer therapy is administered) include reducing the need for second-course chemotherapy due to an ineffective first course, a shorter but more intense first course of chemotherapy, and recurrence prevention. Nevertheless, G-CSFs themselves are expensive. Hence, their administration should be justified both clinically and economically.

Evidence supporting the cost-effectiveness of PPG-CSF in cancer patients is ambiguous. Some clinical trials and observational studies have documented cost-savings from PPG-CSF administration due to reduced hospitalization costs or overall treatment costs.34-36 Other studies have demonstrated no change in costs because the cost savings are offset by G-CSF administration costs.26,37,38 Lyman et al determined that PPGCSF is cost-effective only for patients with >20% risk of chemotherapyinduced febrile neutropenia.21

However, studies based on clinical trials underreport the incidence and costs of treatmentrelated adverse events because they exclude high-risk patients like elderly, have short study durations, and have incomplete adverse event documentation.39-41 The American Society of Clinical Oncology guideline for GCSF use identifies the lack of evidence for G-CSF–related costs and calls for studies establishing the economic impact of G-CSF use.42 The guideline also states that current recommendations for G-CSF use are predominantly based on clinical benefits and not economic outcomes.

The lack of external validity and inadequacies of clinical trials in the elderly call for nationally representative population- based studies to establish the economic impact of PPGCSF use in the elderly.39 This study aims to address this gap and analyzes the effects of PPG-CSF administration on the very first neutropenia hospitalization costs (for patients with any neutropenia hospitalization) and overall first-year Medicare costs after chemotherapy initiation (for the entire study sample) in elderly breast cancer patients.

This paper focuses on the effectiveness of primary prophylaxis and not secondary prophylaxis or therapeutic G-CSF administration. This study also examines the effect of duration of PPG-CSF administration on overall first-year Medicare costs in elderly female breast cancer patients receiving chemotherapy. The commercially available PPG-CSF during the study period (predominantly filgrastim) had to be administered daily for up to 14 days until the absolute neutrophil count reached 10,000 cells per microliter.43 Empirical studies show that PPG-CSF is often administered for 4 to 7 days in practice, and inadequate G-CSF administration is a concern since it is associated with reduced drug effectiveness.30,44,45 Since each shot of PPG-CSF costs more than $250, the study explores costs associated with increased duration of PPG-CSF administration. The effect of PPG-CSF duration on neutropenia hospitalization costs were not estimated due to limited sample size.

Methods

Data Set

This study uses the Surveillance, Epidemiology and End Results (SEER) data from 16 registries containing newly diagnosed breast cancer cases from 1994 to 2002 linked to Medicare claims through 2003. The 16 SEER registries are representative of approximately 25% of the US population, of which the Medicare population is a subset.46 The data are valid, high quality, and complete in terms of cancer incidence and diagnosis reporting in the United States.46

Study Cohort

The study period begins in 1994 after the introduction of G-CSF Healthcare Common Procedure Coding System codes in Medicare claims. To allow for the assessment of prediagnostic comorbidity from 1 year of Medicare claims prior to diagnosis, the study sample was limited to women aged 66 years and older. Women with stage 0 breast cancer were excluded because they do not require chemotherapy. Women with stage IV disease were excluded because chemotherapy is used as palliative rather than curative therapy in these patients. To ensure complete claims, the sample was limited to women enrolled in both Medicare part A and B, and not enrolled in an HMO, for 1 year before and after their diagnosis. The sample was limited to women whose chemotherapy was initiated within the first 6 months of diagnosis because chemotherapy initiation after 6 months could be for recurrence and not for the primary tumor. The initial study sample thus included 10,441 patients aged 66 years and older who were diagnosed with stage I to III breast cancer during 1994 to 2002 and who received chemotherapy within 6 months of diagnosis. The study period was particularly chosen because the period offers a clean sample for exploring the impact of short-acting PPG-CSF on Medicare costs. The utilization of long-acting pegfilgrastim among Medicare patients began in 2003. Unlike short-acting PPG-CSF, pegfilgrastim is administered once per chemotherapy cycle (every 2-3 weeks); currently both shortand long-acting G-CSFs are used.

Study Measures and Framework

Dependent Variables. Two types of dependent variables were used in the analysis. (1) The hospitalization costs for the first neutropenia hospitalization within 3 months and within 6 months after first-course chemotherapy initiation were estimated using Medicare inpatient files. A hospitalization with International Classification of Diseases, Ninth Revision diagnosis code of 288.0X was considered a “neutropenia hospitalization.” The durations of 3 months and 6 months were chosen because 3 to 6 months is the typical duration of first-course chemotherapy during which a chemotherapy-induced neutropenia- hospitalization can occur. (2) Inpatient, outpatient, neutropephysician office, and durable medical equipment claims were used to construct the overall healthcare costs during the first year after chemotherapy initiation.

In this study, cost was measured from Medicare’s (payer’s) perspective; hence, cost is the actual amount paid by Medicare to the provider. Costs were reported in 2002 dollars using an inflation rate of 3%. Due to the right-skewed log-normal distribution of costs, the logarithm of costs were used based on the conclusions from the Box-Cox model specification test. The analysis of the effect of PPG-CSF on the first hospitalization costs was performed only for patients who were hospitalized. The analysis of the effect of PPG-CSF on overall Medicare costs was performed for all patients for a duration of 1 year after chemotherapy initiation (the point of initiation of the exposure), when the bulk of cancer treatment is administered.

Treatment Variables. Use of PPG-CSF was identified by procedure codes for all the commercially available GCSF drugs (ie, filgrastim [J1440 and J1441] and sargramostim [J2820]), from the Medicare claims. A dummy variable was created for whether or not PPG-CSF was administered.

Because G-CSF is administered both as a prophylactic and as a therapeutic drug for neutropenia, primary prophylactic use is hard to distinguish using claims data. However, neutropenic symptoms only begin a week after chemotherapy initiation and peak after 2 weeks.47,48 Consequently, any administration of G-CSF within 5 days of chemotherapy initiation cannot be therapeutic or secondary prophylactic. To prevent misclassification of therapeutic or secondary prophylactic G-CSF use as PPG-CSF, only G-CSF initiated within 5 days of first-course chemotherapy initiation was considered primary prophylaxis, which is consistent with the methods and findings of related studies.11,22,33,44,49 Studies also show that PPG-CSF initiation after the first 5 days of chemotherapy initiation is less effective in preventing neutropenia22,49; hence, the 5-day window is a crucial period to investigate.

Duration of PPG-CSF therapy was defined as a continuous variable measuring the number of consecutive days of PPGCSF administration. Duration was also defined as a dummy variable measuring whether or not PPG-CSF was administered for >5 days (adequate administration) based on previous literature.30,44,,45,49

Confounders. The 3 categories of variables controlled for were: patient sociodemographic, clinical (overall and tumorrelated), and therapeutic characteristics.9,11,50-57 The details about each variable are provided in 2 previously published papers.24,56 Descriptive statistics for the confounders are provided in Table 1. Because administration of PPG-CSF and neutropenia hospitalizations occur as a result of chemotherapy initiation, all the clinical history variables including the modified Charlson Comorbidity Index score, past history of cancer, and history of infections, antibiotic use, and hospitalizations were measured with respect to chemotherapy initiation. In order to ensure that the confounders were pretreatment variables and not those influenced by PPG-CSF administration itself, therapy (eg, chemotherapy) characteristics included only those aspects that were decided upon before the administration of PPG-CSF (eg, characteristics of the first cycle of the first-course chemotherapy).

The variables in each of the categories (patient sociodemographic, clinical, and therapeutic characteristics) were included in the model based on past evidence from the literature.56 For the continuous variables, different specifications and higher-order terms were evaluated, resulting in the inclusion of the square of number of drugs in the first cycle and the square of the duration between the first and second cycle.

Statistical Analysis

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up